Exagen Inc. (XGN) Tops Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts XGN Hot Sheet
Join SI Premium – FREE
Exagen Inc. (NASDAQ: XGN) reported Q2 EPS of ($0.13), $0.06 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $19.94 million versus the consensus estimate of $17.81 million.
For earnings history and earnings-related data on Exagen Inc. (XGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c
- Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
